Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc Net Operating Profit After Tax (NOPAT) 2 year CAGR for the quarter ending December 31, 2023: -13.90%

Allakos Inc Net Operating Profit After Tax (NOPAT) 2 year CAGR is -13.90% for the quarter ending December 31, 2023, a -263.11% change year over year. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Allakos Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2023 was -40,810,342.51, a 79.06% change year over year.
Allakos Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2022 was -194,875,662.03, a -253.78% change year over year.
Allakos Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2021 was -55,083,807.26, a -100.31% change year over year.
Allakos Inc Net Operating Profit After Tax (NOPAT) for the quarter ending March 31, 2020 was -27,499,762.79, a -40.97% change year over year.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends